Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul:30:100669.
doi: 10.1016/j.lanepe.2023.100669. Epub 2023 Jun 15.

Timing and sequence of vaccination against COVID-19 and influenza - Author's reply

Elisabeth A Dulfer  1   2 , Büsra Geckin  1   2 , Esther J M Taks  1   2 , Corine H GeurtsvanKessel  3 , Helga Dijkstra  1   2 , Liesbeth van Emst  1   2 , Christa E van der Gaast-de Jongh  2   4 , Petra C Koopmans  5 , Jorge Domínguez-Andrés  1   2 , Reinout van Crevel  1   2 , Josephine S van de Maat  1   2 , Marien I de Jonge  2   4 , Mihai G Netea  1   2   6
Affiliations

Timing and sequence of vaccination against COVID-19 and influenza - Author's reply

Elisabeth A Dulfer et al. Lancet Reg Health Eur. 2023 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

MGN is a scientific founder of TTxD, Lemba and BioTrip, and a member of the TTxD scientific advisory board. MGN has received research grants from TTxD and GSK. The TACTIC trial was conducted with the ZonMw COVID-19 programme. The other authors have no conflict of interest.

References

    1. Liu J., Liu X., Liu S., Guangting Z. Timing and sequence of vaccination against COVID-19 and influenza (correspondence) Lancet Reg Health Eur. 2023 doi: 10.1016/j.lanepe.2023.100663. - DOI - PMC - PubMed
    1. Dulfer E.A., Geckin B., Taks E.J.M., et al. Timing and sequence of vaccination against COVID-9 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial. Lancet Reg Health Eur. 2023;29:100628. - PMC - PubMed
    1. Walsh E.E., Frenck R.W., Falsey A.R., et al. Safety and immunogenecity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. - PMC - PubMed
    1. Jackson L.A., Anderson E.J., Rouphael N.G., et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N Engl J Med. 2020;383(2):1920–1931. - PMC - PubMed
    1. Izikson R., Brune D., Bolduc J.-S., et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged≥ 65 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022;10(4):392–402. - PMC - PubMed

LinkOut - more resources